论文部分内容阅读
《内科医学年鉴》(Ann Intern Med)杂志2013年6月17日在线发表了一项基于人群的队列研究,该研究指出,老年人联合使用克拉霉素(或红霉素)和经细胞色素P450同工酶3A4(CYP3A4)代谢的他汀类药物时,会增加服用者出现他汀类药物毒性的风险。他汀类药物主要用于血脂异常及心血管疾病的防治,每年接受他汀类药物治疗的患者达数百万。尽管总体而言他汀类药物具有良好的安全性,但美国食品和药品管理局(FDA)已发出警告,要求人们注意常用的他汀类药物与用于HIV感染和肝炎治疗的抗病毒药物之间潜在的相互作用。此外,与阿奇霉素不同,克拉霉素和红霉素可抑制CYP3A4,而且这种抑制可导致那些经由CYP3A4代谢的他汀类药物血药浓度增加。
Ann Intern Med magazine published a cohort-based cohort study online on June 17, 2013, which indicated that older adults combined clarithromycin (or erythromycin) and cytochrome P450 Statins metabolizing isoenzyme 3A4 (CYP3A4) increase the risk of statin toxicity in the user. Statins are mainly used to prevent and treat dyslipidemia and cardiovascular diseases. Millions of patients receive statins each year. Despite the overall safety of statins, the U.S. Food and Drug Administration (FDA) has warned that it calls attention to the potential gap between commonly used statins and antiviral drugs used in the treatment of HIV infection and hepatitis Interaction. In addition, unlike azithromycin, clarithromycin and erythromycin can inhibit CYP3A4, and this inhibition can lead to an increase in plasma concentrations of statins that metabolize via CYP3A4.